Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.62 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 2/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320849 | 0.77 | ADORA2A (0.41) | ADORA1ADORA2AYTHDC1CYP1A2CYP2D6 | |
| SCHEMBL30572667 | 0.77 | ADORA1 (0.60) | ADORA1ADORA2AYTHDC1CYP1A2CYP2D6 | |
| SCHEMBL3857168 | 0.77 | ADORA1 (0.60) | ADORA1ADORA2AYTHDC1CYP1A2CYP2D6 | |
| SCHEMBL5801450 | 0.77 | ADORA1 (0.60) | ADORA1ADORA2AYTHDC1CYP1A2CYP2D6 | |
| SCHEMBL18721931 | 0.77 | ADORA1 (0.60) | ADORA1ADORA2AYTHDC1CYP1A2CYP2D6 | |
| SCHEMBL106573 | 0.77 | ADORA2A (1.00) | ADORA1ADORA2AYTHDC1CDK1ADORA2B | |
| SCHEMBL1193370 | 0.77 | ADORA2A (0.37) | ADORA1ADORA2AYTHDC1CYP1A2CYP2D6 | |
| SCHEMBL130453 | 0.77 | ADORA1 (0.60) | ADORA1ADORA2AYTHDC1CYP1A2CYP2D6 | |
| SCHEMBL4734999 | 0.77 | ADORA1 (0.60) | ADORA1ADORA2AYTHDC1CYP1A2CYP2D6 | |
| SCHEMBL7147821 | 0.75 | ADORA2A (0.96) | ADORA1ADORA2AYTHDC1CDK1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119117-A1 | MODIFIED 5' CAP FOR MRNA AND METHODS OF USE THEREOF | PRIME MEDICINE, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210340169-A1 | CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2021-11-04 | — | — | US | disclosed |
| EP-3892618-A1 | 4-PYRIDINYL FORMAMIDE COMPOUND OR DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | Qingdao KingAgroot Chemical Compound Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2020-04-16 | — | — | US | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070232507-A1 | Amine reaction compounds comprising one or more active ingredient | THE PROCTER & GAMBLE COMPANY ATTENTION: CHIEF PATENT COUNSEL (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070208170-A1 | INTERMEDIATE AND PROCESS FOR PREPARING OF BETA- ANOMER ENRICHED 21-DEOXY,21,21-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDES | DABUR PHARMA LIMITED | 2007-09-06 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-7235647-B2 | Intermediate and process for preparing of β- anomer enriched 21-deoxy,21,21-difluoro-D-ribofuranosyl nucleosides | DABUR PHARMA LIMITED (IN) | 2007-06-26 | — | — | US | disclosed |
| US-20070099818-A1 | Amine reaction compounds comprising one or more active ingredient | THE PROCTER & GAMBLE COMPANY (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099818-A1 | Amine reaction compounds comprising one or more active ingredient | THE PROCTER & GAMBLE COMPANY (US) | 2007-05-03 | — | — | US | disclosed |
| US-7186700-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | IDENIX PHARMACEUTICALS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | STING1, CGAS, TLR9 | ADORA1 2287/4885ADORA2A 2409/4885YTHDC1 3655/4885 |
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | ADORA1 32/4885ADORA2A 64/4885YTHDC1 1124/4885 |
| US-20070208170-A1 | INTERMEDIATE AND PROCESS FOR PREPARING OF BETA- ANOMER ENRICHED 21-DEOXY,21,21-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDES | GART, ST6GAL1, B4GALT1 | ADORA1 748/4885ADORA2A 757/4885YTHDC1 676/4885 |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ADORA1 32/4885ADORA2A 73/4885YTHDC1 985/4885 |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | ADORA1 2255/4885ADORA2A 3033/4885YTHDC1 4227/4885 |
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | ADORA1 36/4885ADORA2A 72/4885YTHDC1 951/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | ADORA1 763/4885ADORA2A 336/4885YTHDC1 2961/4885 |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | ADORA1 32/4885ADORA2A 73/4885YTHDC1 985/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | ADORA1 3802/4885ADORA2A 3238/4885YTHDC1 334/4885 |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | ADORA1 1640/4885ADORA2A 900/4885YTHDC1 2667/4885 |
| US-20210340169-A1 | CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF | STING1, CGAS, TLR9 | ADORA1 257/4885ADORA2A 354/4885YTHDC1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.